ZNF133 Is Associated with Infliximab Responsiveness in Patients with Inflammatory Bowel Diseases.

ZNF133 Is Associated with Infliximab Responsiveness in Patients with Inflammatory Bowel Diseases. J Gastroenterol Hepatol. 2019 Mar 09;: Authors: Jung ES, Choi KW, Kim SW, Hübenthal M, Mucha S, Park J, Park Z, Ellinghaus D, Schreiber S, Franke A, Oh WY, Cheon JH Abstract BACKGROUND AND AIM: Infliximab has been widely prescribed for treating inflammatory bowel disease (IBD). However, the response rates to infliximab differ among patients. Therefore, we aimed to identify the genetic and clinical markers that predict infliximab response. METHODS: A total of 139 Korean patients with IBD…

Read More

Best practices on immunomodulators and biological agents for Ulcerative colitis and Crohn’s disease in Asia.

Best practices on immunomodulators and biological agents for Ulcerative colitis and Crohn’s disease in Asia. J Gastroenterol Hepatol. 2019 Mar 08;: Authors: Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, Makharia GK, Pisespongsa P, Chen MH, Ran ZH, Ye BD, Park DI, Ling KL, Ong D, Ahuja V, Goh KL, Sollano J, Lim WC, Leung WK, Raja Ali RA, Wu DC, Ong E, Mustaffa N, Limsrivilai J, Hisamatsu T, Yang SK, Ouyang Q, Geary R, De Silva JH, Rerknimitr R, Simadibrata M, Abdullah M, Leong RWL,…

Read More

Long-term efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study.

Related Articles Long-term efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study. J Gastroenterol Hepatol. 2019 Mar 03;: Authors: Kim NH, Lee JH, Hong SN, Yoon H, Kang HW, Lee SH, Im JP, Cha JM, Eun CS, Kim JW, Choi CH, Park DI Abstract BACKGROUND AND AIM: A biosimilar of infliximab, CT-P13 (Remsima®) has the potential to reduce treatment costs and enhance access to biological therapy for inflammatory bowel disease (IBD) patients. However, long-term clinical data on its use for…

Read More

Association between dietary iron and zinc intake and development of ulcerative colitis: A case-control study in Japan.

Association between dietary iron and zinc intake and development of ulcerative colitis: A case-control study in Japan. J Gastroenterol Hepatol. 2019 Mar 01;: Authors: Kobayashi Y, Ohfuji S, Kondo K, Fukushima W, Sasaki S, Kamata N, Yamagami H, Fujiwara Y, Suzuki Y, Hirota Y, Japanese Case-Control Study Group for Ulcerative Colitis Abstract BACKGROUND AND AIM: The prevalence of ulcerative colitis (UC) has been increasing in Japan. Trace elements such as iron, zinc, magnesium and copper, can cause digestive symptoms where there is a deficiency or excess. We focused on the…

Read More

Long-term outcomes of patients with Crohn’s disease who received infliximab or adalimumab as the first-line biologics.

Long-term outcomes of patients with Crohn’s disease who received infliximab or adalimumab as the first-line biologics. J Gastroenterol Hepatol. 2019 Feb 06;: Authors: Inokuchi T, Takahashi S, Hiraoka S, Toyokawa T, Takagi S, Takemoto K, Miyaike J, Fujimoto T, Higashi R, Morito Y, Nawa T, Suzuki S, Nishimura M, Inoue M, Kato J, Okada H Abstract BACKGROUND AND AIM: Although previous studies compared the efficacy of infliximab (IFX) versus adalimumab (ADA) as the first-line biologics for Crohn’s disease (CD), the difference in long-term prognosis based on which biologic was used…

Read More

Outcomes of ulcerative colitis-associated dysplasia patients referred for potential endoscopic submucosal dissection.

Outcomes of ulcerative colitis-associated dysplasia patients referred for potential endoscopic submucosal dissection. J Gastroenterol Hepatol. 2019 Feb 06;: Authors: Yang DH, Kim J, Song EM, Chang K, Lee SH, Hwang SW, Park SH, Ye BD, Byeon JS, Myung SJ, Yang SK Abstract BACKGROUND: The feasibility of endoscopic submucosal dissection (ESD) as a treatment option for dysplasia in ulcerative colitis (UC) has been reported but the associated therapeutic decision-making and clinical outcomes have not been extensively investigated. METHODS: We retrospectively reviewed 25 UC patients who were referred for potential ESD of…

Read More

Regional Variations in the Use of Biologics and Immunomodulators among Korean Patients with Inflammatory Bowel Diseases.

Regional Variations in the Use of Biologics and Immunomodulators among Korean Patients with Inflammatory Bowel Diseases. J Gastroenterol Hepatol. 2019 Jan 23;: Authors: Han M, Jung YS, Cheon JH, Park S Abstract BACKGROUND: Variation in medical care can be an obstacle to improving quality and outcome of treatment. We conducted a nationwide, population-based study to identify regional variations in medication prescription rates in Korean patients with inflammatory bowel diseases (IBD). METHODS: Using the National Health Insurance claims, we collected data on patients diagnosed with IBD (8,974 cases of Crohn’s disease…

Read More

Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients.

Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients. J Gastroenterol Hepatol. 2018 Dec 27;: Authors: Van den Berghe N, Verstockt B, Tops S, Ferrante M, Vermeire S, Gils A Abstract BACKGROUND AND AIM: The pivotal GEMINI trials reported low immunogenicity of vedolizumab. However, anti-vedolizumab antibodies (AVA) are frequently underestimated since most assays are not drug-tolerant and unable to detect anti-drug antibodies while there is drug in the circulation. This study aimed to explore which anti-drug antibody assay is best suited to detect AVA…

Read More

Compound polysaccharides ameliorate experimental colitis by modulating gut microbiota composition and function.

Compound polysaccharides ameliorate experimental colitis by modulating gut microbiota composition and function. J Gastroenterol Hepatol. 2018 Dec 27;: Authors: Cai Y, Liu W, Lin Y, Zhang S, Zou B, Xiao D, Lin L, Zhong Y, Zheng H, Liao Q, Xie Z Abstract BACKGROUND AND AIM: Inflammatory bowel disease (IBD) results from a dysregulated immune response to intestinal microbial flora in individuals with genetic predisposition(s). This study aimed to determine the effects of compound polysaccharides (CP) containing yam polysaccharide and inulin on the rat model of colitis induced by 2,4,6-trinitrobenzenesulfonic acid…

Read More

Incidence and clinical impact of perianal disease in patients with ulcerative colitis: A nationwide population-based study.

Related Articles Incidence and clinical impact of perianal disease in patients with ulcerative colitis: A nationwide population-based study. J Gastroenterol Hepatol. 2018 Nov 22;: Authors: Song EM, Lee HS, Kim YJ, Oh EH, Ham NS, Kim J, Hwang SW, Park SH, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK Abstract BACKGROUND AND AIM: The risk and clinical impact of perianal disease (PAD) in ulcerative colitis (UC) patients have not been fully evaluated. We investigated the incidence of PAD in UC patients and compared clinical characteristics and outcomes of…

Read More
<< Go Back